Wall Street brokerages expect Scpharmaceuticals Inc (NASDAQ:SCPH) to report ($0.58) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Scpharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.57) and the lowest estimate coming in at ($0.59). The firm is expected to report its next earnings results on Monday, August 6th.
According to Zacks, analysts expect that Scpharmaceuticals will report full-year earnings of ($2.22) per share for the current financial year, with EPS estimates ranging from ($2.35) to ($2.09). For the next year, analysts expect that the firm will post earnings of ($2.40) per share, with EPS estimates ranging from ($2.48) to ($2.31). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that follow Scpharmaceuticals.
Scpharmaceuticals (NASDAQ:SCPH) last released its earnings results on Monday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.51) by $0.04.
Scpharmaceuticals traded down $0.36, reaching $5.53, on Thursday, Marketbeat reports. 299,600 shares of the company’s stock were exchanged, compared to its average volume of 111,203. Scpharmaceuticals has a twelve month low of $5.25 and a twelve month high of $18.17. The firm has a market capitalization of $112.18 million and a PE ratio of -0.66. The company has a debt-to-equity ratio of 0.10, a current ratio of 19.23 and a quick ratio of 19.23.
Institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System acquired a new stake in Scpharmaceuticals in the first quarter valued at $139,000. Schwab Charles Investment Management Inc. acquired a new stake in Scpharmaceuticals in the first quarter valued at $167,000. Monashee Investment Management LLC acquired a new stake in Scpharmaceuticals in the fourth quarter valued at $230,000. Bank of New York Mellon Corp acquired a new stake in Scpharmaceuticals in the fourth quarter valued at $414,000. Finally, Millennium Management LLC acquired a new stake in Scpharmaceuticals in the fourth quarter valued at $462,000. 44.87% of the stock is currently owned by institutional investors.
scPharmaceuticals Inc, a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.